Etanercept in Adult Patients with Early Onset Ankylosing Spondylitis
ROBERT D. INMAN, DANIEL O. CLEGG, JOHN C. DAVIS, JAMES B. WHITMORE, and ALAN SOLINGER
Objective. To determine whether twice-weekly subcutaneous etanercept improves the signs and symptoms of adult patients with early onset ankylosing spondylitis (AS).
Methods. A retrospective analysis was performed on a subgroup of patients with AS with onset < 18 years of age from a multicenter, double-blind, placebo-controlled, randomized study of etanercept in the treatment of patients with AS. Twenty patients met criteria and are presented.
Results. As early as week four, 5/9 (56%) patients who received etanercept achieved an Assessments in Ankylosing Spondylitis 20% response (ASAS 20) versus only 1/11 (9%) of those who received placebo (p = 0.032). The observed ASAS 20 response continued through week 24, with 6/9 (66%) patients receiving etanercept responding, versus 2/11 of patients receiving placebo (p = 0.025).
Conclusion. Etanercept improves signs and symptoms of early onset AS in adult patients for at least 24 weeks. (J Rheumatol 2006;33:1634–6)
Key Indexing Terms:
From the Toronto Western Hospital, Toronto, Ontario, Canada; University of Utah Medical Center, Salt Lake City, Utah; University of California San Francisco, San Francisco; and Amgen Inc., Thousand Oaks, California, USA.
R.D. Inman, MD, Toronto Western Hospital; D.O. Clegg, MD, University of Utah Medical Center; J.C. Davis, MD, MPH, University of California San Francisco; J.B. Whitmore, PhD; A. Solinger, MD, Amgen Inc.
Address reprint requests to Dr. R.D. Inman, Toronto Western Hospital, 399 Bathurst St., Toronto, ON M5T 2S8, Canada.
Accepted for publication March 28, 2006.